IO Biotech Inc expected to post a loss of 36 cents a share - Earnings Preview

IO Biotech

12/08/2025 13:42

IO Biotech Inc IOBT.OQ IOBT.O is expected to  show no change in quarterly revenue when it reports  results on August 14 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for IO Biotech Inc is for a loss of 36 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for IO Biotech Inc is $9.00, about 88.3% above its last closing price of $1.05

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.45
-0.38
-0.34
Beat
10.5
Dec. 31 2025
-0.41
-0.39
-0.48
Missed
-23.1
Sep. 30 2024
-0.28
-0.29
-0.36
Missed
-25.2​
Jun. 30 2024
-0.35
-0.35
-0.31
Beat
11.4
​​Mar. 31 2024
-0.37
-0.36
-0.30
Beat
16.7
Dec. 31 2023
-0.43
-0.39
-0.40
Missed
-3.1​
Sep. 30 2023
-0.42
-0.44
-0.43
Beat
3.2
Jun. 30 2023
-0.66
-0.66
-0.74
Missed
-12.1

This summary was machine generated August 12 at 12:42 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)